Tag Archives: head & neck cancer

Modulight Spotlights: LASER-SHARP RESEARCH – September 2023

September 12, 2023 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – September 2023 Head & neck cancer is world’s sixth most common cancer, with increasing incidence and poor survival. A new study by P. Enzian & R. Rahmanzadeh at University of Lübeck, studied combining chemotherapy with photochemical internalization for more effective H&N cancer treatment in vitro. Photochemical internalization using photosensitizer fimaporfin, activated with Modulight’s ML6600 laser, was shown to increase drug’s efficacy by means of better drug delivery inside the cells. As a result, tumor cell death was achieved using 20-fold Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – August 2022

August 10, 2022 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – August 2022 Impressive research on head & neck cancer was published by Obaid Lab for molecular imaging and optical nanotherapeutics, at University of Texas, Dallas. The group used Modulight’s ML6500 for a subtherapeutic modulation of tumor microenvironment of H&N. This significantly improved delivery of molecular imaging agent to the tumors as well as improved diagnostic accuracy in detecting tumor tissue by fluorescence. Since incomplete resection and consequent recurrences are common problem with current H&N cancer treatment, this discovery answers unmet Continue reading →

Light delivery optimization for H&N cancer treatment

August 30, 2021 by Modulight Content
No comments
Results Illumination with one fiber Some level of tissue heating was observed at all used light intensities. At lower intensities (60-100 mW/cm), less than 5% of the tumor was subjected to >60 ⁰C temperature, a point where irreversible thermal damage will immediately occur (photothermal ablation). At intensities of 150-200 mW/cm, 15-20% of the tumor was at >60 ⁰C temperature. At 400 mW/cm, which is FDA-recommended light irradiance for iPDT, a substantial portion of the tumor, up to 60%, was above 60 ⁰C.   Above figures Continue reading →Customer case Roswell Park Comprehensive Cancer Center was founded in 1898 as the first institute in the US devoted exclusively to cancer treatment and research. It is also the place where photodynamic therapy (PDT) was developed in the late 1970s by Thomas Dougherty. The PDT center at Roswell Park is a leader in the use of photodynamic therapy for treating different cancers. Research work includes treatment planning and light dosimetry for interstitial and intraoperative PDT to improve the quality of life and survival of cancer patients Continue reading →

Rapid Depletion of Intratumoral Regulatory T cells Induces Synchronized CD8 T and NK Cell Activation and IFN-γ-dependent Tumor Vessel Regression

June 1, 2021 by Modulight
No comments
Published in: Cancer Research Authors: Yutaka Kurebayashi, Colleen P. Olkowski, Kelly C. Lane, Olga V. Vasalatiy, Biying C. Xu, Ryuhei Okada, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi, Noriko Sato    Published in: Cancer Research Authors: Yutaka Kurebayashi, Colleen P. Olkowski, Kelly C. Lane, Olga V. Vasalatiy, Biying C. Xu, Ryuhei Okada, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi, Noriko Sato   Tumor-infiltrating regulatory T cells (Tregs) were selectively depleted using anti-CD25 antibody fragment mediated NIR-PIT with ML7710 (50 J/cm2) in tumor-bearing mice. This induced transient IFN-γ expression in CD8 T and NK cells, which lead to efficient and rapid tumor vessel regression, intratumoral ischemia, and tumor necrosis/apoptosis and growth suppression. These results indicate the pivotal Continue reading →

Irradiance controls photodynamic efficacy and tissue heating in experimental tumours: implication for interstitial PDT of locally advanced cancer

October 24, 2018 by Modulight
No comments
Published in: British Journal of Cancer Authors: Gal Shafirstein, David A. Bellnier, Emily Oakley, Sasheen Hamilton, Michael Habitzruther, Lawrence Tworek, Alan Hutson, Joseph A. Spernyak, Sandra Sexton, Leslie Curtin, Steven G. Turowski, Hassan Arshad, Barbara Henderson    Published in: British Journal of Cancer Authors: Gal Shafirstein, David A. Bellnier, Emily Oakley, Sasheen Hamilton, Michael Habitzruther, Lawrence Tworek, Alan Hutson, Joseph A. Spernyak, Sandra Sexton, Leslie Curtin, Steven G. Turowski, Hassan Arshad, Barbara Henderson   Currently delivered light dose (J/cm2) is the principal parameter guiding interstitial photodynamic therapy (I-PDT) of refractory locally advanced cancer. The aim of this study was to investigate the impact of light dose rate (irradiance, mW/cm2) and associated heating on tumour response and cure. Laser was used to activate Continue reading →

Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial

July 27, 2016 by Modulight
No comments
Published in: Lancet Oncology Authors: Ahmed A Sultan, Waseem Jerjes, Kristian Berg, Anders Høgset, Charles A Mosse, Rifat Hamoudi, Zaid Hamdoon, Celia Simeon, Dawn Carnell, Martin Forster, Colin Hopper    Published in: Lancet Oncology Authors: Ahmed A Sultan, Waseem Jerjes, Kristian Berg, Anders Høgset, Charles A Mosse, Rifat Hamoudi, Zaid Hamdoon, Celia Simeon, Dawn Carnell, Martin Forster, Colin Hopper   Photochemical internalization with bleomycin was studied in a Phase 1, first-in-man trial for local recurrent, advanced, or metastatic H&N cancer. Modulight laser was used for activation of TPCS2a photosensitizer at the surface of the target tumor. 12 patients completed the 3-month follow-up, with maximum tolerated dose of TPCS2a being established to 1.0 mg/kg.   Read Continue reading →

EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer

May 10, 2016 by Modulight
No comments
Published in: Journal of Controlled Release Authors: Pieter B.A.A. van Driel, Martin C. Boonstra, Maxime D. Slooter, Raimond Heukers, Marieke A. Stammes, Thomas J.A. Snoeks, Henriette S. de Bruijn, Paul J. van Diest, Alexander L. Vahrmeijer, Paul M.P. van Bergen en Henegouwen, Cornelis J.H. van de Velde, Clemens W.G.M. Löwik, Dominic J. Robinson, Sabrina Oliveira    Published in: Journal of Controlled Release Authors: Pieter B.A.A. van Driel, Martin C. Boonstra, Maxime D. Slooter, Raimond Heukers, Marieke A. Stammes, Thomas J.A. Snoeks, Henriette S. de Bruijn, Paul J. van Diest, Alexander L. Vahrmeijer, Paul M.P. van Bergen en Henegouwen, Cornelis J.H. van de Velde, Clemens W.G.M. Löwik, Dominic J. Robinson, Sabrina Oliveira   Photodynamic therapy (PDT) induces cell death through local light activation of a photosensitizer (PS) and has been used to treat head and neck cancers. Yet, common PS lack tumor Continue reading →